查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128286

胰島素市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Insulin Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 224 Pages | 商品交期: 2-3個工作天內

價格

胰島素市場成長要素

全球胰島素市場預計到2025年將達到289.1億美元，2026年成長至300.3億美元，到2034年達到415.1億美元，預測期內複合年成長率（CAGR）為4.13%。北美地區在全球胰島素市場中佔據領先地位，預計到2025年將佔據36.63%的市場佔有率，這主要得益於其龐大的糖尿病患者群體、先進的醫療基礎設施以及胰島素類似物和創新型胰島素輸注系統的廣泛主導。

胰島素市場包括人類胰島素、胰島素類似物、生物類似胰島素產品、用於治療第1型糖尿病和胰島素依賴型第2型糖尿病的先進胰島素製劑。市場成長的促進因素包括全球糖尿病盛行率上升、診斷率提高、長效和速效胰島素類似物供應增加、價格合理的胰島素產品可及性提高以及胰島素給藥技術的持續創新。

胰島素市場趨勢

胰島素市場變革的關鍵趨勢之一是胰島素輸注技術的進步。醫護人員和患者擴大採用預填充填充胰島素筆、智慧胰島素筆、胰島素幫浦、貼片幫浦和自動胰島素輸注系統，這些技術提高了輸注的準確性、患者的便利性和血糖控制水平。胰島素幫浦與持續血糖監測 (CGM) 系統以及智慧輸注演算法的結合，實現了更個人化的糖尿病護理，同時也提高了治療依從性。這些創新推動了對與先進輸注裝置相容的胰島素產品的需求不斷成長，從而加強了糖尿病的長期管理。

市場促進因素

全球糖尿病盛行率持續上升，仍是胰島素市場的主要驅動力。隨著第1型和第2型糖尿病患者數量的不斷增加，對終身胰島素治療的需求也持續成長。第1型糖尿病患者需要終身使用胰島素，而許多晚期第二型糖尿病患者最終會從口服藥物過渡到胰島素治療。肥胖率上升、人口老化、久坐的生活方式以及糖尿病篩檢計畫的改進，進一步擴大了接受胰島素治療的患者群體。製造商正透過提高產能、拓展生物相似藥產品線以及改善已開發市場和新興市場的胰島素供應來應對這一需求。

市場限制因素

儘管臨床需求不斷成長，但高昂的治療費用仍限制市場成長。長期胰島素治療對許多患者來說是一項沉重的經濟負擔，尤其是在健保覆蓋範圍有限的國家。高額的自付費用往往會導致處方箋延遲、劑量減少或胰島素使用受限，對治療順從性產生負面影響。同時，各國政府和醫療保險機構正在實施更嚴格的報銷政策，並鼓勵使用成本較低的生物相似藥和人類胰島素產品，這給高階胰島素生產商帶來了價格壓力。

市場機遇

人們對糖尿病管理的日益關注為胰島素市場帶來了巨大的機會。公共衛生宣傳活動、患者教育計畫以及疾病認知的提高，正在推動糖尿病的早期診斷、及時啟動治療以及胰島素治療依從性的提升。隨著人們對糖尿病併發症、血糖值監測和胰島素使用的認知不斷加深，對胰島素類似物、生物相似藥和便捷注射裝置的需求也不斷成長。新興經濟體醫療保健覆蓋範圍的擴大，預計也將促使一些診斷不明確的患者最終成為長期胰島素使用者。

市場挑戰

其他糖尿病治療方案的競爭是胰島素生產商面臨的一大挑戰。 GLP-1受體促效劑、GIP/GLP-1聯合治療和SGLT2抑制劑的日益普及，導致許多第二型糖尿病患者延遲開始胰島素治療。這些新型療法還具有其他益處，例如減輕體重、保護心血管和改善腎功能，使其成為糖尿病早期治療的理想選擇。因此，胰島素生產商正日益關注產品的價格優勢、使用便利性和先進的給藥技術，以維持市場競爭力。

細分分析

按類型分類，到2025年，胰島素類似物將佔據市場主導地位。這主要歸功於其卓越的臨床療效、給藥方式的柔軟性以及醫生群體的廣泛支持。預計在預測期內，人類胰島素的複合年成長率將達到3.17%。

按產品類型分類，長效和超長效胰島素將在 2025 年佔據最大的市場佔有率，這主要得益於基礎胰島素療法的日益普及，預計到 2026 年將佔市場佔有率的 32.9%。速效胰島素預計將以 4.26% 的複合年成長率成長。

按藥物類型分類，品牌藥預計將在2025年佔據最大的市場佔有率，這主要得益於醫生對其的信任度高、醫保覆蓋範圍廣以及完善的全球分銷網路。生物相似藥預計將以5.88%的複合年成長率達到最高成長。

按疾病分類，2 型糖尿病佔據市場主導地位，預計到 2026 年將佔市場佔有率的 71.9%，反映出全球胰島素依賴型患者數量的增加。

按年齡層別分類，由於成人糖尿病盛行率較高，預計到 2025 年成人市場將佔據最大的市場佔有率，而兒童市場預計將實現 3.66% 的複合年成長率。

按給藥途徑分類，皮下給藥途徑佔據市場主導地位，這得益於胰島素筆、胰島素筆芯、管瓶和胰島素幫浦相容製劑的廣泛應用，預計到 2026 年將佔市場佔有率的 98.4%。吸入式胰島素領域預計將以最高的複合年成長率成長，達到 7.81%。

按分銷管道分類，預計零售藥局和藥局將在 2025 年佔據主導地位，並在 2026 年佔據 55.7% 的市場佔有率，而網路藥局預計將以 5.60% 的複合年成長率成長。

區域分析

由於胰島素類似物的廣泛應用、完善的保險報銷體係以及先進的胰島素輸注技術，預計北美市場規模將在2025年維持在105.9億美元，繼續保持全球最大市場的地位。美國市場預計2026年將達到約100.6億美元，約佔全球市場的33.5%。

預計歐洲市場將以3.22%的複合年成長率成長，這主要得益於健全的公共醫療保險體系和生物類似胰島素產品日益普及。德國市場預計到2026年將達到19億美元，而英國市場預計將達到17.1億美元。

亞太地區預計2026年市場規模將達到72.8億美元，主要促進因素包括龐大的糖尿病患者群體、醫療基礎設施的改善、診斷率的提高以及本地胰島素產量的擴大。印度預計到2026年市場規模將達11億美元，日本同期預計也將達到11億美元。

在拉丁美洲、中東和非洲地區，由於糖尿病盛行率上升、醫療保健服務可近性提高以及胰島素療法的廣泛應用，預計將穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢
  • 市場挑戰

第4章：主要考慮因素

  • 2025年主要國家和地區糖尿病盛行率
  • 管道分析：按主要公司分類
  • 主要國家和地區的監管趨勢
  • 主要國家的還款方案
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：按主要公司分類

第5章：2021-2034年全球胰島素市場分析、洞察與預測

  • 市場分析、洞察與預測：按類型
    • 人類胰島素
    • 胰島素類似物
  • 市場分析、洞察與預測：按產品類型分類
    • 長效和超長效胰島素
    • 速效胰島素
    • 中效胰島素
    • 組合
    • 其他
  • 市場分析、洞察與預測：按藥物類型分類
    • 品牌
    • 生物相似藥
  • 市場分析、洞察與預測：按疾病類型分類
    • 1型糖尿病
    • 2型糖尿病
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按給藥途徑
    • 皮下
    • 吸入
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥局和藥房
    • 網路藥局及其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲胰島素市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Novo Nordisk
    • Eli Lilly and Company
    • Sanofi
    • Biocon Limited
    • Gan & Lee Pharmaceuticals
    • Wockhardt Limited
    • Julphar Diabetes
    • MannKind Corporation
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • The United Laboratories International Holdings Ltd.
Product Code: FBI116988

Growth Factors of insulin Market

The global insulin market was valued at USD 28.91 billion in 2025 and is projected to grow from USD 30.03 billion in 2026 to USD 41.51 billion by 2034, registering a CAGR of 4.13% during the forecast period. North America dominated the global insulin market with a 36.63% market share in 2025, supported by a large diabetic population, advanced healthcare infrastructure, and widespread adoption of insulin analogs and innovative insulin delivery systems.

The insulin market includes human insulin, insulin analogs, biosimilar insulin products, and advanced insulin formulations used for the treatment of type 1 diabetes and insulin-dependent type 2 diabetes. Market growth is driven by the rising prevalence of diabetes worldwide, increasing diagnosis rates, greater adoption of long-acting and rapid-acting insulin analogs, expanding access to affordable insulin products, and continuous innovation in insulin delivery technologies.

Insulin Market Trends

One of the major trends transforming the insulin market is the advancement of insulin delivery technologies. Healthcare providers and patients are increasingly adopting prefilled insulin pens, smart insulin pens, insulin pumps, patch pumps, and automated insulin delivery systems that improve dosing accuracy, patient convenience, and glucose management. Integration of insulin pumps with continuous glucose monitoring (CGM) systems and intelligent dosing algorithms is enabling more personalized diabetes care while improving treatment adherence. These innovations are supporting higher demand for insulin products compatible with advanced delivery devices and enhancing long-term diabetes management.

Market Drivers

The increasing global prevalence of diabetes remains the primary driver of the insulin market. Growing numbers of patients diagnosed with both type 1 and type 2 diabetes continue to increase demand for lifelong insulin therapy. While type 1 diabetes patients require insulin throughout their lives, many patients with advanced type 2 diabetes eventually transition from oral medications to insulin therapy. Rising obesity rates, aging populations, sedentary lifestyles, and improved diabetes screening programs are further expanding the insulin-treated patient base. Manufacturers are responding by increasing production capacity, expanding biosimilar portfolios, and improving insulin accessibility across developed and emerging markets.

Market Restraints

High treatment costs continue to restrain market growth despite increasing clinical demand. Long-term insulin therapy represents a significant financial burden for many patients, particularly in countries with limited insurance coverage. High out-of-pocket expenses often result in delayed prescriptions, reduced dosing, or insulin rationing, negatively affecting treatment adherence. At the same time, governments and healthcare payers are implementing stricter reimbursement policies while encouraging the adoption of lower-cost biosimilar and human insulin products, creating pricing pressure on premium branded insulin manufacturers.

Market Opportunities

Growing awareness regarding diabetes management presents a major opportunity for the insulin market. Public health campaigns, patient education programs, and improved disease awareness are encouraging earlier diagnosis, timely treatment initiation, and better adherence to insulin therapy. Increased understanding of diabetes complications, glucose monitoring, and insulin usage is supporting greater demand for insulin analogs, biosimilars, and user-friendly delivery devices. Expanding healthcare access in emerging economies is also expected to convert underdiagnosed patients into long-term insulin users.

Market Challenges

Competition from alternative diabetes therapies represents a significant challenge for insulin manufacturers. The growing use of GLP-1 receptor agonists, dual GIP/GLP-1 therapies, and SGLT2 inhibitors is delaying insulin initiation in many patients with type 2 diabetes. These newer therapies offer additional benefits such as weight reduction, cardiovascular protection, and improved kidney outcomes, making them attractive alternatives during earlier stages of diabetes treatment. Consequently, insulin manufacturers are increasingly focusing on affordability, convenience, and advanced delivery technologies to maintain market competitiveness.

Segmentation Analysis

Based on type, insulin analogs dominated the market in 2025, owing to superior clinical performance, dosing flexibility, and wider physician preference. Human insulin is projected to grow at a CAGR of 3.17% during the forecast period.

By product type, long-acting and ultra-long-acting insulin accounted for the largest market share in 2025 and is expected to hold 32.9% of the market in 2026, driven by widespread use of basal insulin therapy. Rapid-acting insulin is anticipated to expand at a CAGR of 4.26%.

Based on drug type, the branded segment held the largest market share in 2025, supported by strong physician confidence, broad reimbursement, and established global distribution networks. The biosimilars segment is projected to grow at the fastest CAGR of 5.88%.

By disease type, type 2 diabetes dominated the market and is expected to account for 71.9% of the market in 2026, reflecting the growing number of insulin-dependent patients worldwide.

Based on age group, the adults segment held the largest market share in 2025 due to the high prevalence of diabetes among adults, while the pediatrics segment is expected to register a CAGR of 3.66%.

By route of administration, the subcutaneous segment dominated the market and is projected to account for 98.4% of the market in 2026, supported by widespread use of insulin pens, cartridges, vials, and pump-compatible formulations. The inhaled insulin segment is expected to grow at the highest CAGR of 7.81%.

Based on distribution channel, retail pharmacies and drug stores held the leading position in 2025 and are expected to account for 55.7% of the market in 2026, while online pharmacies are projected to grow at a CAGR of 5.60%.

Regional Analysis

North America remained the largest regional market with a valuation of USD 10.59 billion in 2025, supported by widespread use of insulin analogs, strong reimbursement systems, and advanced insulin delivery technologies. The U.S. market is estimated to reach approximately USD 10.06 billion in 2026, accounting for around 33.5% of the global market.

Europe is projected to grow at a CAGR of 3.22%, driven by strong public reimbursement systems and increasing adoption of biosimilar insulin products. Germany is expected to reach USD 1.90 billion in 2026, while the U.K. market is projected at USD 1.71 billion.

Asia Pacific is expected to reach USD 7.28 billion in 2026, supported by a large diabetic population, improving healthcare infrastructure, rising diagnosis rates, and expanding local insulin manufacturing. India is projected to reach USD 1.10 billion in 2026, while Japan is expected to reach USD 1.10 billion during the same period.

Latin America and the Middle East & Africa are expected to witness steady growth due to rising diabetes prevalence, expanding healthcare access, and increasing adoption of insulin therapies.

Competitive Landscape

The insulin market is moderately consolidated, with leading companies focusing on expanding insulin portfolios, biosimilar development, affordability programs, regional manufacturing, and innovative delivery technologies. Major companies include Novo Nordisk, Eli Lilly and Company, Sanofi, Biocon Limited, Gan & Lee Pharmaceuticals, Wockhardt Limited, Julphar Diabetes, MannKind Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., and The United Laboratories International Holdings Ltd. Strategic initiatives including biosimilar launches, manufacturing expansion, product approvals, and partnerships continue to strengthen market competition.

Conclusion

The global insulin market is expected to experience steady growth as diabetes prevalence continues to rise worldwide and demand for effective long-term insulin therapy increases. Technological advancements in insulin delivery systems, broader availability of biosimilar products, and greater awareness of diabetes management are supporting sustained market expansion. Although affordability challenges and competition from alternative diabetes therapies remain significant obstacles, continued innovation, improved patient access, and expanding healthcare infrastructure are expected to drive future growth. With the market projected to increase from USD 30.03 billion in 2026 to USD 41.51 billion by 2034 at a CAGR of 4.13%, insulin manufacturers are expected to focus on affordable, patient-friendly, and technologically advanced treatment solutions to strengthen their market position.

Segmentation By Type, Product Type, Drug Type, Disease Type, Age Group, Route of Administration, Distribution Channel, and Region

By Type * Human Insulin

  • Insulin Analogs

By Product Type * Long-acting & Ultra-long-acting Insulin

  • Rapid-acting Insulin
  • Intermediate-acting Insulin
  • Combination
  • Others

By Drug Type * Branded

  • Biosimilar

By Disease Type * Diabetes Type 1

  • Diabetes Type 2
  • Others

By Age Group * Pediatrics

  • Adults

By Route of Administration * Subcutaneous

  • Inhaled
  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies & Drug Stores
  • Online Pharmacies & Others

By Region * North America (By Type, Product Type, Drug Type, Disease Type, Age Group, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Type, Product Type, Drug Type, Disease Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product Type, Drug Type, Disease Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Product Type, Drug Type, Disease Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product Type, Drug Type, Disease Type, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends
  • 3.5. Market Challenges

4. Key Insights

  • 4.1. Prevalence of Diabetes, By Key Countries/Region, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Regulatory Scenario, By Key Countries/Region
  • 4.4. Reimbursement Scenario, By Key Countries/Region
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. New Product Launches, By Key Players

5. Global Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Human Insulin
    • 5.1.2. Insulin Analogs
  • 5.2. Market Analysis, Insights and Forecast - By Product Type
    • 5.2.1. Long-acting & Ultra-long-acting Insulin
    • 5.2.2. Rapid-acting Insulin
    • 5.2.3. Intermediate-acting Insulin
    • 5.2.4. Combination
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Drug Type
    • 5.3.1. Branded
    • 5.3.2. Biosimilar
  • 5.4. Market Analysis, Insights and Forecast - By Disease Type
    • 5.4.1. Diabetes Type 1
    • 5.4.2. Diabetes Type 2
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Age Group
    • 5.5.1. Pediatrics
    • 5.5.2. Adults
  • 5.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.6.1. Subcutaneous
    • 5.6.2. Inhaled
    • 5.6.3. Others
  • 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.7.1. Hospital Pharmacies
    • 5.7.2. Retail Pharmacies & Drug Stores
    • 5.7.3. Online Pharmacies & Others
  • 5.8. Market Analysis, Insights and Forecast - Region
    • 5.8.1. North America
    • 5.8.2. Europe
    • 5.8.3. Asia Pacific
    • 5.8.4. Latin America
    • 5.8.5. Middle East & Africa

6. North America Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Human Insulin
    • 6.1.2. Insulin Analogs
  • 6.2. Market Analysis, Insights and Forecast - By Product Type
    • 6.2.1. Long-acting & Ultra-long-acting Insulin
    • 6.2.2. Rapid-acting Insulin
    • 6.2.3. Intermediate-acting Insulin
    • 6.2.4. Combination
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Drug Type
    • 6.3.1. Branded
    • 6.3.2. Biosimilar
  • 6.4. Market Analysis, Insights and Forecast - By Disease Type
    • 6.4.1. Diabetes Type 1
    • 6.4.2. Diabetes Type 2
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Age Group
    • 6.5.1. Pediatrics
    • 6.5.2. Adults
  • 6.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.6.1. Subcutaneous
    • 6.6.2. Inhaled
    • 6.6.3. Others
  • 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.7.1. Hospital Pharmacies
    • 6.7.2. Retail Pharmacies & Drug Stores
    • 6.7.3. Online Pharmacies & Others
  • 6.8. Market Analysis, Insights and Forecast - By Country
    • 6.8.1. U.S.
    • 6.8.2. Canada

7. Europe Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Human Insulin
    • 7.1.2. Insulin Analogs
  • 7.2. Market Analysis, Insights and Forecast - By Product Type
    • 7.2.1. Long-acting & Ultra-long-acting Insulin
    • 7.2.2. Rapid-acting Insulin
    • 7.2.3. Intermediate-acting Insulin
    • 7.2.4. Combination
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Drug Type
    • 7.3.1. Branded
    • 7.3.2. Biosimilar
  • 7.4. Market Analysis, Insights and Forecast - By Disease Type
    • 7.4.1. Diabetes Type 1
    • 7.4.2. Diabetes Type 2
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Age Group
    • 7.5.1. Pediatrics
    • 7.5.2. Adults
  • 7.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.6.1. Subcutaneous
    • 7.6.2. Inhaled
    • 7.6.3. Others
  • 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.7.1. Hospital Pharmacies
    • 7.7.2. Retail Pharmacies & Drug Stores
    • 7.7.3. Online Pharmacies & Others
  • 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.8.1. U.K.
    • 7.8.2. Germany
    • 7.8.3. France
    • 7.8.4. Italy
    • 7.8.5. Spain
    • 7.8.6. Scandinavia
    • 7.8.7. Rest of Europe

8. Asia Pacific Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Human Insulin
    • 8.1.2. Insulin Analogs
  • 8.2. Market Analysis, Insights and Forecast - By Product Type
    • 8.2.1. Long-acting & Ultra-long-acting Insulin
    • 8.2.2. Rapid-acting Insulin
    • 8.2.3. Intermediate-acting Insulin
    • 8.2.4. Combination
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Drug Type
    • 8.3.1. Branded
    • 8.3.2. Biosimilar
  • 8.4. Market Analysis, Insights and Forecast - By Disease Type
    • 8.4.1. Diabetes Type 1
    • 8.4.2. Diabetes Type 2
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Age Group
    • 8.5.1. Pediatrics
    • 8.5.2. Adults
  • 8.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.6.1. Subcutaneous
    • 8.6.2. Inhaled
    • 8.6.3. Others
  • 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.7.1. Hospital Pharmacies
    • 8.7.2. Retail Pharmacies & Drug Stores
    • 8.7.3. Online Pharmacies & Others
  • 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.8.1. China
    • 8.8.2. Japan
    • 8.8.3. India
    • 8.8.4. Australia
    • 8.8.5. Southeast Asia
    • 8.8.6. Rest of Asia Pacific

9. Latin America Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Human Insulin
    • 9.1.2. Insulin Analogs
  • 9.2. Market Analysis, Insights and Forecast - By Product Type
    • 9.2.1. Long-acting & Ultra-long-acting Insulin
    • 9.2.2. Rapid-acting Insulin
    • 9.2.3. Intermediate-acting Insulin
    • 9.2.4. Combination
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Drug Type
    • 9.3.1. Branded
    • 9.3.2. Biosimilar
  • 9.4. Market Analysis, Insights and Forecast - By Disease Type
    • 9.4.1. Diabetes Type 1
    • 9.4.2. Diabetes Type 2
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Age Group
    • 9.5.1. Pediatrics
    • 9.5.2. Adults
  • 9.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.6.1. Subcutaneous
    • 9.6.2. Inhaled
    • 9.6.3. Others
  • 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Retail Pharmacies & Drug Stores
    • 9.7.3. Online Pharmacies & Others
  • 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.8.1. Brazil
    • 9.8.2. Mexico
    • 9.8.3. Rest of Latin America

10. Middle East & Africa Insulin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Human Insulin
    • 10.1.2. Insulin Analogs
  • 10.2. Market Analysis, Insights and Forecast - By Product Type
    • 10.2.1. Long-acting & Ultra-long-acting Insulin
    • 10.2.2. Rapid-acting Insulin
    • 10.2.3. Intermediate-acting Insulin
    • 10.2.4. Combination
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Drug Type
    • 10.3.1. Branded
    • 10.3.2. Biosimilar
  • 10.4. Market Analysis, Insights and Forecast - By Disease Type
    • 10.4.1. Diabetes Type 1
    • 10.4.2. Diabetes Type 2
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Age Group
    • 10.5.1. Pediatrics
    • 10.5.2. Adults
  • 10.6. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.6.1. Subcutaneous
    • 10.6.2. Inhaled
    • 10.6.3. Others
  • 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Retail Pharmacies & Drug Stores
    • 10.7.3. Online Pharmacies & Others
  • 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.8.1. GCC
    • 10.8.2. South Africa
    • 10.8.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Novo Nordisk
    • 11.2.2. Eli Lilly and Company
    • 11.2.3. Sanofi
    • 11.2.4. Biocon Limited
    • 11.2.5. Gan & Lee Pharmaceuticals
    • 11.2.6. Wockhardt Limited
    • 11.2.7. Julphar Diabetes
    • 11.2.8. MannKind Corporation
    • 11.2.9. Tonghua Dongbao Pharmaceutical Co., Ltd.
    • 11.2.10. The United Laboratories International Holdings Ltd.

List of Tables

  • Table 1: Global Insulin Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 2: Global Insulin Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 3: Global Insulin Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 4: Global Insulin Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 5: Global Insulin Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 6: Global Insulin Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 7: Global Insulin Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 8: Global Insulin Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 9: North America Insulin Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 10: North America Insulin Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 11: North America Insulin Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 12: North America Insulin Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 13: North America Insulin Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 14: North America Insulin Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 15: North America Insulin Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 16: North America Insulin Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 17: Europe Insulin Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 18: Europe Insulin Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 19: Europe Insulin Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 20: Europe Insulin Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 21: Europe Insulin Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 22: Europe Insulin Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 23: Europe Insulin Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 24: Europe Insulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Asia Pacific Insulin Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 26: Asia Pacific Insulin Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 27: Asia Pacific Insulin Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 28: Asia Pacific Insulin Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 29: Asia Pacific Insulin Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 30: Asia Pacific Insulin Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 31: Asia Pacific Insulin Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 32: Asia Pacific Insulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 33: Latin America Insulin Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 34: Latin America Insulin Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 35: Latin America Insulin Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 36: Latin America Insulin Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 37: Latin America Insulin Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 38: Latin America Insulin Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 39: Latin America Insulin Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 40: Latin America Insulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 41: Middle East & Africa Insulin Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 42: Middle East & Africa Insulin Market Revenue (USD billion) Forecast, By Product Type, 2021-2034
  • Table 43: Middle East & Africa Insulin Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 44: Middle East & Africa Insulin Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 45: Middle East & Africa Insulin Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 46: Middle East & Africa Insulin Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 47: Middle East & Africa Insulin Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 48: Middle East & Africa Insulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Insulin Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Insulin Market Value Share (%), By Type, 2025 & 2034
  • Figure 3: Global Insulin Market Value Share (%), By Product Type, 2025 & 2034
  • Figure 4: Global Insulin Market Value Share (%), By Drug Type, 2025 & 2034
  • Figure 5: Global Insulin Market Value Share (%), By Disease Type, 2025 & 2034
  • Figure 6: Global Insulin Market Value Share (%), By Age Group, 2025 & 2034
  • Figure 7: Global Insulin Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 8: Global Insulin Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 9: Global Insulin Market Value Share (%), By Region, 2025 & 2034
  • Figure 10: North America Insulin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 11: North America Insulin Market Value Share (%), By Type, 2025
  • Figure 12: North America Insulin Market Value (USD billion), By Product Type, 2025 & 2034
  • Figure 13: North America Insulin Market Value Share (%), By Product Type, 2025
  • Figure 14: North America Insulin Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 15: North America Insulin Market Value Share (%), By Drug Type, 2025
  • Figure 16: North America Insulin Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 17: North America Insulin Market Value Share (%), By Disease Type, 2025
  • Figure 18: North America Insulin Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 19: North America Insulin Market Value Share (%), By Age Group, 2025
  • Figure 20: North America Insulin Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 21: North America Insulin Market Value Share (%), By Route of Administration, 2025
  • Figure 22: North America Insulin Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 23: North America Insulin Market Value Share (%), By Distribution Channel, 2025
  • Figure 24: North America Insulin Market Value (USD billion), by Country, 2025 & 2034
  • Figure 25: North America Insulin Market Value Share (%), by Country, 2025
  • Figure 26: Europe Insulin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 27: Europe Insulin Market Value Share (%), By Type, 2025
  • Figure 28: Europe Insulin Market Value (USD billion), By Product Type, 2025 & 2034
  • Figure 29: Europe Insulin Market Value Share (%), By Product Type, 2025
  • Figure 30: Europe Insulin Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 31: Europe Insulin Market Value Share (%), By Drug Type, 2025
  • Figure 32: Europe Insulin Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 33: Europe Insulin Market Value Share (%), By Disease Type, 2025
  • Figure 34: Europe Insulin Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 35: Europe Insulin Market Value Share (%), By Age Group, 2025
  • Figure 36: Europe Insulin Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 37: Europe Insulin Market Value Share (%), By Route of Administration, 2025
  • Figure 38: Europe Insulin Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 39: Europe Insulin Market Value Share (%), By Distribution Channel, 2025
  • Figure 40: Europe Insulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 41: Europe Insulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 42: Asia Pacific Insulin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 43: Asia Pacific Insulin Market Value Share (%), By Type, 2025
  • Figure 44: Asia Pacific Insulin Market Value (USD billion), By Product Type, 2025 & 2034
  • Figure 45: Asia Pacific Insulin Market Value Share (%), By Product Type, 2025
  • Figure 46: Asia Pacific Insulin Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 47: Asia Pacific Insulin Market Value Share (%), By Drug Type, 2025
  • Figure 48: Asia Pacific Insulin Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 49: Asia Pacific Insulin Market Value Share (%), By Disease Type, 2025
  • Figure 50: Asia Pacific Insulin Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 51: Asia Pacific Insulin Market Value Share (%), By Age Group, 2025
  • Figure 52: Asia Pacific Insulin Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 53: Asia Pacific Insulin Market Value Share (%), By Route of Administration, 2025
  • Figure 54: Asia Pacific Insulin Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 55: Asia Pacific Insulin Market Value Share (%), By Distribution Channel, 2025
  • Figure 56: Asia Pacific Insulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 57: Asia Pacific Insulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 58: Latin America Insulin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 59: Latin America Insulin Market Value Share (%), By Type, 2025
  • Figure 60: Latin America Insulin Market Value (USD billion), By Product Type, 2025 & 2034
  • Figure 61: Latin America Insulin Market Value Share (%), By Product Type, 2025
  • Figure 62: Latin America Insulin Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 63: Latin America Insulin Market Value Share (%), By Drug Type, 2025
  • Figure 64: Latin America Insulin Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 65: Latin America Insulin Market Value Share (%), By Disease Type, 2025
  • Figure 66: Latin America Insulin Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 67: Latin America Insulin Market Value Share (%), By Age Group, 2025
  • Figure 68: Latin America Insulin Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 69: Latin America Insulin Market Value Share (%), By Route of Administration, 2025
  • Figure 70: Latin America Insulin Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 71: Latin America Insulin Market Value Share (%), By Distribution Channel, 2025
  • Figure 72: Latin America Insulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 73: Latin America Insulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 74: Middle East & Africa Insulin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 75: Middle East & Africa Insulin Market Value Share (%), By Type, 2025
  • Figure 76: Middle East & Africa Insulin Market Value (USD billion), By Product Type, 2025 & 2034
  • Figure 77: Middle East & Africa Insulin Market Value Share (%), By Product Type, 2025
  • Figure 78: Middle East & Africa Insulin Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 79: Middle East & Africa Insulin Market Value Share (%), By Drug Type, 2025
  • Figure 80: Middle East & Africa Insulin Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 81: Middle East & Africa Insulin Market Value Share (%), By Disease Type, 2025
  • Figure 82: Middle East & Africa Insulin Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 83: Middle East & Africa Insulin Market Value Share (%), By Age Group, 2025
  • Figure 84: Middle East & Africa Insulin Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 85: Middle East & Africa Insulin Market Value Share (%), By Route of Administration, 2025
  • Figure 86: Middle East & Africa Insulin Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 87: Middle East & Africa Insulin Market Value Share (%), By Distribution Channel, 2025
  • Figure 88: Middle East & Africa Insulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 89: Middle East & Africa Insulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 90: Global Insulin Market Share (%), by Company, 2025